Literature DB >> 23507284

Comparison of oseltamivir and oseltamivir carboxylate concentrations in venous plasma, venous blood, and capillary blood in healthy volunteers.

Insti Instiaty1, Niklas Lindegardh, Podjanee Jittmala, Warunee Hanpithakpong, Daniel Blessborn, Sasithon Pukrittayakamee, Nicholas J White, Joel Tarning.   

Abstract

Oseltamivir and oseltamivir carboxylate concentrations were measured in venous plasma, venous blood, and capillary blood taken simultaneously from 24 healthy volunteers. Median (range) venous-blood-to-plasma ratios were 1.42 (0.920 to 1.97) for oseltamivir and 0.673 (0.564 to 0.814) for oseltamivir carboxylate. Capillary blood/venous plasma ratios were 1.32 (0.737 to 3.16) for oseltamivir and 0.685 (0.502 to 1.34) for oseltamivir carboxylate. Oseltamivir concentrations in venous and capillary blood were similar. Oseltamivir carboxylate showed a time-dependent distribution between venous and capillary blood.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23507284      PMCID: PMC3716162          DOI: 10.1128/AAC.02408-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers.

Authors:  J W Massarella; G Z He; A Dorr; K Nieforth; P Ward; A Brown
Journal:  J Clin Pharmacol       Date:  2000-08       Impact factor: 3.126

Review 2.  Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics.

Authors:  P H Hinderling
Journal:  Pharmacol Rev       Date:  1997-09       Impact factor: 25.468

3.  Use of saliva and capillary blood samples as substitutes for venous blood sampling in pharmacokinetic investigations of artemisinin.

Authors:  T Gordi; T N Hai; N M Hoai; M Thyberg; M Ashton
Journal:  Eur J Clin Pharmacol       Date:  2000-11       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

Authors:  G He; J Massarella; P Ward
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

5.  Pharmacokinetics and delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon using site-specific delivery capsules.

Authors:  Charles Oo; Paul Snell; Joanne Barrett; Albert Dorr; Baolian Liu; Ian Wilding
Journal:  Int J Pharm       Date:  2003-05-12       Impact factor: 5.875

6.  Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Anthony E Fiore; Alicia Fry; David Shay; Larisa Gubareva; Joseph S Bresee; Timothy M Uyeki
Journal:  MMWR Recomm Rep       Date:  2011-01-21

7.  Accuracy of cyclosporin measurements made in capillary blood samples obtained by skin puncture.

Authors:  G Merton; K Jones; M Lee; A Johnston; D W Holt
Journal:  Ther Drug Monit       Date:  2000-10       Impact factor: 3.681

8.  Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of oseltamivir and its metabolite oseltamivir carboxylate in plasma, saliva and urine.

Authors:  N Lindegårdh; W Hanpithakpong; Y Wattanagoon; P Singhasivanon; N J White; N P J Day
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-09-19       Impact factor: 3.205

9.  Pharmacokinetics of high-dose oseltamivir in healthy volunteers.

Authors:  Y Wattanagoon; K Stepniewska; N Lindegårdh; S Pukrittayakamee; U Silachamroon; W Piyaphanee; T Singtoroj; W Hanpithakpong; G Davies; J Tarning; W Pongtavornpinyo; C Fukuda; P Singhasivanon; N P J Day; N J White
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

10.  Comparison of venous and capillary blood sampling for the clinical determination of tobramycin serum concentrations.

Authors:  A S Lewis; G Taylor; H O Williams; M H Lewis
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

View more
  3 in total

1.  Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants.

Authors:  Mikael Boberg; Marc Vrana; Aanchal Mehrotra; Robin E Pearce; Andrea Gaedigk; Deepak Kumar Bhatt; J Steven Leeder; Bhagwat Prasad
Journal:  Drug Metab Dispos       Date:  2016-11-28       Impact factor: 3.922

2.  Comparison of Capillary and Venous Drug Concentrations After Administration of a Single Dose of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole.

Authors:  Bart Remmerie; Marc De Meulder; Sveta Weiner; Adam Savitz
Journal:  Clin Pharmacol Drug Dev       Date:  2016-09-28

3.  Land O'Lakes Workshop on Microsampling: Enabling Broader Adoption.

Authors:  Enaksha R Wickremsinhe; Qin C Ji; Carol R Gleason; Melanie Anderson; Brian P Booth
Journal:  AAPS J       Date:  2020-10-23       Impact factor: 4.009

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.